查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1402924

硬皮症诊断与治疗市场 - 全球产业分析、规模、份额、成长、趋势与预测，2023-2031 年

Scleroderma Diagnostics and Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 176 Pages | 商品交期: 2-10个工作天内

价格

硬皮症诊断和治疗市场 - 报告范围

TMR 关于全球硬皮症诊断和治疗市场的报告研究了过去以及当前的成长趋势和机会，以获得 2023 年至 2031 年预测期内市场指标的宝贵见解。该报告提供了全球硬皮症诊断的收入2017-2031 年期间的治疗市场，以2023 年为基准年，2031 年为预测年。该报告也提供了2023年至2031年全球硬皮症诊断和治疗市场的年复合成长率（CAGR %）。

该报告是经过广泛研究后编写的。初级研究涉及大部分研究工作，其中分析师对关键意见领袖、行业领导者和舆论製造者进行了采访。二次研究涉及参考主要参与者的产品文献、年度报告、新闻稿和相关文件，以了解硬皮症诊断和治疗市场。

市场概况
2023年市场价值 22亿美元
2031 年市场价值 46 亿美元
CAGR 8.7%

该报告深入研究了全球硬皮症诊断和治疗市场的竞争格局。全球硬皮症诊断和治疗市场的主要参与者已经确定，并且每位参与者都已根据各种属性进行了分析。公司概况、财务状况、最新发展和 SWOT 是本报告中介绍的全球硬皮症诊断和治疗市场参与者的属性。

目录

第 1 章：执行摘要

第 2 章：市场概述

  • 市场区隔
  • 市场走向
  • 市场动态
  • 波特五力分析
  • 监管分析
  • 价值链分析
  • 产品规格分析
  • 製造流程概览
  • 成本结构分析

第 3 章：COVID-19 影响分析

第 4 章：价格趋势分析

第 5 章：全球市场分析与预测：按药物类别，2023-2031

  • 简介和定义
  • 全球市场价值预测：依药品类别，2023-2031
    • 皮质类固醇
    • 免疫抑制剂
    • 内皮素受体激动剂
    • 钙通道阻断剂
    • PD5抑制剂
    • 螯合剂
    • 前列环素类似物
    • H2 阻断剂
    • 质子帮浦抑制剂
    • ACE抑制剂
  • 全球市场吸引力：按药品类别

第 6 章：全球市场分析与预测：依指标划分，2023-2031

  • 简介和定义
  • 全球市场价值预测：依指标划分，2023-2031
    • 系统性
    • 在地化
  • 全球市场吸引力：依指标分类

第 7 章：全球市场分析与预测：按诊断测试类型，2023-2031

  • 简介和定义
  • 全球市场价值预测：依诊断测试类型，2023-2031
    • 皮肤切片
    • 影像技术
    • 验血
    • 心电图和超音波心动图
    • 肺功能测试
  • 全球市场吸引力：按诊断测试类型

第 8 章：全球市场分析与预测：按地区划分，2023-2031

  • 主要发现
  • 全球市场价值预测：按地区，2023-2031
    • 北美洲
    • 欧洲
    • 亚太地区
    • 中东和非洲
    • 拉丁美洲
  • 全球市场吸引力：按地区划分

第 9 章：2023-2031 年北美市场分析与预测

第 10 章：2023-2031 年欧洲市场分析与预测

第 11 章：2023-2031 年亚太市场分析与预测

第 12 章：2023-2031 年拉丁美洲市场分析与预测

第 13 章：2023-2031 年中东和非洲市场分析与预测

第 14 章：竞争格局

  • 2022 年全球公司市占率分析
  • 公司简介（详细资讯 - 概述、财务状况、近期发展和策略）
    • Johnson & Johnson Services, Inc.
    • Boehringer Ingelheim
    • Bayer AG
    • Cytori Therapeutics, Inc.
    • Corbus Pharmaceuticals Holdings Inc.
    • Cumberland Pharmaceuticals, Inc.
    • Gilead Sciences, Inc.
    • Sanofi SA
    • Pfizer Inc.
    • F. Hoffmann-La Roche AG
    • Merck & Co., Inc.

第 15 章：初步研究：主要见解

第 16 章：附录

Product Code: TMRGL2498

Scleroderma Diagnostics and Therapeutics Market - Scope of Report

TMR's report on the global scleroderma diagnostics and therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global scleroderma diagnostics and therapeutics market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global scleroderma diagnostics and therapeutics market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the scleroderma diagnostics and therapeutics market.

Market Snapshot
Market Value in 2023US$ 2.2 Bn
Market Value in 2031US$ 4.6 Bn
CAGR8.7%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global scleroderma diagnostics and therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global scleroderma diagnostics and therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global scleroderma diagnostics and therapeutics market.

The report delves into the competitive landscape of the global scleroderma diagnostics and therapeutics market. Key players operating in the global scleroderma diagnostics and therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global scleroderma diagnostics and therapeutics market profiled in this report.

Key Questions Answered in Global scleroderma diagnostics and therapeutics Market Report:

  • What is the sales/revenue generated by scleroderma diagnostics and therapeutics across all regions during the forecast period?
  • What are the opportunities in the global scleroderma diagnostics and therapeutics market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Scleroderma Diagnostics and Therapeutics Market - Research Objectives and Research Approach

The comprehensive report on the global scleroderma diagnostics and therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global scleroderma diagnostics and therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global scleroderma diagnostics and therapeutics market.

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Key Facts and Figures
  • 1.4. Trends Impacting Market
  • 1.5. TMR's Growth Opportunity Wheel

2. Market Overview

  • 2.1. Market Segmentation
  • 2.2. Market Trends
  • 2.3. Market Dynamics
    • 2.3.1. Drivers
    • 2.3.2. Restraints
    • 2.3.3. Opportunities
  • 2.4. Porter's Five Forces Analysis
  • 2.5. Regulatory Analysis
  • 2.6. Value Chain Analysis
    • 2.6.1. List of Raw Material Suppliers
    • 2.6.2. List of Key Manufacturers
    • 2.6.3. List of Suppliers/ Distributors
    • 2.6.4. List of Potential Customers
  • 2.7. Product Specification Analysis
  • 2.8. Overview of Manufacturing Process
  • 2.9. Cost Structure Analysis

3. COVID-19 Impact Analysis

4. Price Trend Analysis

5. Global Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, by Drug Class, 2023-2031

  • 5.1. Introduction and Definitions
  • 5.2. Global Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
    • 5.2.1. Corticosteroids
    • 5.2.2. Immunosuppressive Agents
    • 5.2.3. Endothelin Receptor Agonists
    • 5.2.4. Calcium Channel Blockers
    • 5.2.5. PD5-Inhibitors
    • 5.2.6. Chelating Agents
    • 5.2.7. Prostacyclin Analogues
    • 5.2.8. H2 Blockers
    • 5.2.9. Proton Pump Inhibitors
    • 5.2.10. ACE Inhibitors
  • 5.3. Global Scleroderma Diagnostics and Therapeutics Market Attractiveness, by Drug Class

6. Global Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, by Indication, 2023-2031

  • 6.1. Introduction and Definitions
  • 6.2. Global Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
    • 6.2.1. Systemic
    • 6.2.2. Localized
  • 6.3. Global Scleroderma Diagnostics and Therapeutics Market Attractiveness, by Indication

7. Global Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, by Diagnostic Test Type, 2023-2031

  • 7.1. Introduction and Definitions
  • 7.2. Global Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
    • 7.2.1. Skin Biopsy
    • 7.2.2. Imaging Techniques
    • 7.2.3. Blood Test
    • 7.2.4. Electrocardiogram and Echocardiogram
    • 7.2.5. Pulmonary Function Tests
  • 7.3. Global Scleroderma Diagnostics and Therapeutics Market Attractiveness, by Diagnostic Test Type

8. Global Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, by Region, 2023-2031

  • 8.1. Key Findings
  • 8.2. Global Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Region, 2023-2031
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Middle East & Africa
    • 8.2.5. Latin America
  • 8.3. Global Scleroderma Diagnostics and Therapeutics Market Attractiveness, by Region

9. North America Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, 2023-2031

  • 9.1. Key Findings
  • 9.2. North America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
  • 9.3. North America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
  • 9.4. North America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • 9.5. North America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Country, 2023-2031
    • 9.5.1. U.S. Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
    • 9.5.2. U.S. Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
    • 9.5.3. U.S. Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
    • 9.5.4. Canada Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
    • 9.5.5. Canada Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
    • 9.5.6. Canada Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • 9.6. North America Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis

10. Europe Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, 2023-2031

  • 10.1. Key Findings
  • 10.2. Europe Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
  • 10.3. Europe Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
  • 10.4. Europe Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • 10.5. Europe Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Country and Sub-region, 2023-2031
    • 10.5.1. Germany Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
    • 10.5.2. Germany Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
    • 10.5.3. Germany Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
    • 10.5.4. France Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
    • 10.5.5. France Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
    • 10.5.6. France Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
    • 10.5.7. U.K. Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
    • 10.5.8. U.K. Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
    • 10.5.9. U.K. Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
    • 10.5.10. Italy Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
    • 10.5.11. Italy. Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
    • 10.5.12. Italy Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
    • 10.5.13. Russia & CIS Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
    • 10.5.14. Russia & CIS Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
    • 10.5.15. Russia & CIS Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
    • 10.5.16. Rest of Europe Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
    • 10.5.17. Rest of Europe Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
    • 10.5.18. Rest of Europe Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • 10.6. Europe Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis

11. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, 2023-2031

  • 11.1. Key Findings
  • 11.2. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class
  • 11.3. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
  • 11.4. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • 11.5. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Country and Sub-region, 2023-2031
    • 11.5.1. China Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
    • 11.5.2. China Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
    • 11.5.3. China Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
    • 11.5.4. Japan Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
    • 11.5.5. Japan Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
    • 11.5.6. Japan Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
    • 11.5.7. India Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
    • 11.5.8. India Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
    • 11.5.9. India Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
    • 11.5.10. ASEAN Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
    • 11.5.11. ASEAN Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
    • 11.5.12. ASEAN Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
    • 11.5.13. Rest of Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
    • 11.5.14. Rest of Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
    • 11.5.15. Rest of Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • 11.6. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis

12. Latin America Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, 2023-2031

  • 12.1. Key Findings
  • 12.2. Latin America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
  • 12.3. Latin America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
  • 12.4. Latin America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • 12.5. Latin America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Country and Sub-region, 2023-2031
    • 12.5.1. Brazil Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
    • 12.5.2. Brazil Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
    • 12.5.3. Brazil Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
    • 12.5.4. Mexico Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
    • 12.5.5. Mexico Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
    • 12.5.6. Mexico Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
    • 12.5.7. Rest of Latin America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
    • 12.5.8. Rest of Latin America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
    • 12.5.9. Rest of Latin America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • 12.6. Latin America Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis

13. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, 2023-2031

  • 13.1. Key Findings
  • 13.2. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
  • 13.3. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
  • 13.4. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • 13.5. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Country and Sub-region, 2023-2031
    • 13.5.1. GCC Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
    • 13.5.2. GCC Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
    • 13.5.3. GCC Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
    • 13.5.4. South Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
    • 13.5.5. South Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
    • 13.5.6. South Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
    • 13.5.7. Rest of Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
    • 13.5.8. Rest of Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
    • 13.5.9. Rest of Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • 13.6. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis

14. Competition Landscape

  • 14.1. Global Scleroderma Diagnostics and Therapeutics Company Market Share Analysis, 2022
  • 14.2. Company Profiles (Details - Overview, Financials, Recent Developments, and Strategy)
    • 14.2.1. Johnson & Johnson Services, Inc.
      • 14.2.1.1. Company Description
      • 14.2.1.2. Business Overview
      • 14.2.1.3. Financial Overview
      • 14.2.1.4. Strategic Overview
    • 14.2.2. Boehringer Ingelheim
      • 14.2.2.1. Company Description
      • 14.2.2.2. Business Overview
      • 14.2.2.3. Financial Overview
      • 14.2.2.4. Strategic Overview
    • 14.2.3. Bayer AG
      • 14.2.3.1. Company Description
      • 14.2.3.2. Business Overview
      • 14.2.3.3. Financial Overview
      • 14.2.3.4. Strategic Overview
    • 14.2.4. Cytori Therapeutics, Inc.
      • 14.2.4.1. Company Description
      • 14.2.4.2. Business Overview
      • 14.2.4.3. Financial Overview
      • 14.2.4.4. Strategic Overview
    • 14.2.5. Corbus Pharmaceuticals Holdings Inc.
      • 14.2.5.1. Company Description
      • 14.2.5.2. Business Overview
      • 14.2.5.3. Financial Overview
      • 14.2.5.4. Strategic Overview
    • 14.2.6. Cumberland Pharmaceuticals, Inc.
      • 14.2.6.1. Company Description
      • 14.2.6.2. Business Overview
      • 14.2.6.3. Financial Overview
      • 14.2.6.4. Strategic Overview
    • 14.2.7. Gilead Sciences, Inc.
      • 14.2.7.1. Company Description
      • 14.2.7.2. Business Overview
      • 14.2.7.3. Financial Overview
      • 14.2.7.4. Strategic Overview
    • 14.2.8. Sanofi S.A.
      • 14.2.8.1. Company Description
      • 14.2.8.2. Business Overview
      • 14.2.8.3. Financial Overview
      • 14.2.8.4. Strategic Overview
    • 14.2.9. Pfizer Inc.
      • 14.2.9.1. Company Description
      • 14.2.9.2. Business Overview
      • 14.2.9.3. Financial Overview
      • 14.2.9.4. Strategic Overview
    • 14.2.10. F. Hoffmann-La Roche AG
      • 14.2.10.1. Company Description
      • 14.2.10.2. Business Overview
      • 14.2.10.3. Financial Overview
      • 14.2.10.4. Strategic Overview
    • 14.2.11. Merck & Co., Inc.
      • 14.2.11.1. Company Description
      • 14.2.11.2. Business Overview
      • 14.2.11.3. Financial Overview
      • 14.2.11.4. Strategic Overview

15. Primary Research: Key Insights

16. Appendix

List of Tables

  • Table 01: Global Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Drug Class, 2023-2031
  • Table 02: Global Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Indication, 2023-2031
  • Table 03: Global Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • Table 04: Global Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Region, 2023-2031
  • Table 05: North America Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Country, 2023-2031
  • Table 06: North America Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Drug Class, 2023-2031
  • Table 07: North America Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Indication, 2023-2031
  • Table 08: North America Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • Table 09: Europe Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2023-2031
  • Table 10: Europe Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Drug Class, 2023-2031
  • Table 11: Europe Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Indication, 2023-2031
  • Table 12: Europe Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • Table 13: Asia Pacific Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2023-2031
  • Table 14: Asia Pacific Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Drug Class, 2023-2031
  • Table 15: Asia Pacific Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Indication, 2023-2031
  • Table 16: Asia Pacific Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • Table 17: Latin America Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2023-2031
  • Table 18: Latin America Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Drug Class, 2023-2031
  • Table 19: Latin America Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Indication, 2023-2031
  • Table 20: Latin America Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • Table 21: Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2023-2031
  • Table 22: Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Drug Class, 2023-2031
  • Table 23: Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Indication, 2023-2031
  • Table 24: Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031

List of Figures

  • Figure 01: Global Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) and Distribution (%), by Region, 2023 and 2031
  • Figure 02: Global Scleroderma Diagnostics and Therapeutics Market Revenue (US$ Bn), by Drug Class, 2022
  • Figure 03: Global Scleroderma Diagnostics and Therapeutics Market Value Share, by Drug Class, 2022
  • Figure 04: Global Scleroderma Diagnostics and Therapeutics Market Revenue (US$ Bn), by Indication, 2022
  • Figure 05: Global Scleroderma Diagnostics and Therapeutics Market Value Share, by Indication, 2022
  • Figure 06: Global Scleroderma Diagnostics and Therapeutics Market Revenue (US$ Bn), by Diagnostic Test Type, 2022
  • Figure 07: Global Scleroderma Diagnostics and Therapeutics Market Value Share, by Diagnostic Test Type, 2022
  • Figure 08: Global Scleroderma Diagnostics and Therapeutics Market Value Share, by Region, 2022
  • Figure 09: Global Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, 2023-2031
  • Figure 10: Global Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2031
  • Figure 11: Global Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 12: Global Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Indication, 2023 and 2031
  • Figure 13: Global Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 14: Global Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Diagnostic Test Type, 2023 and 2031
  • Figure 15: Global Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Diagnostic Test Type, 2022-2031
  • Figure 16: Global Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Region, 2023 and 2031
  • Figure 17: Global Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 18: North America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2023-2031
  • Figure 19: North America Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 20: North America Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Country, 2023 and 2031
  • Figure 21: North America Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2031
  • Figure 22: North America Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Indication, 2023 and 2031
  • Figure 23: North America Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Diagnostic Test Type, 2023 and 2031
  • Figure 24: North America Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 25: North America Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 26:North America Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Diagnostic Test Type, 2022-2031
  • Figure 27: Europe Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2023-2031
  • Figure 28: Europe Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 29: Europe Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
  • Figure 30: Europe Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2031
  • Figure 31: Europe Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Indication, 2023 and 2031
  • Figure 32: Europe Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Diagnostic Test Type, 2023 and 2031
  • Figure 33: Europe Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 34: Europe Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 35: Europe Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Diagnostic Test Type, 2022-2031
  • Figure 36: Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2023-2031
  • Figure 37: Asia Pacific Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 38: Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
  • Figure 39: Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2031
  • Figure 40: Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Indication, 2023 and 2031
  • Figure 41: Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Diagnostic Test Type, 2023 and 2031
  • Figure 42: Asia Pacific Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 43: Asia Pacific Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 44: Asia Pacific Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Diagnostic Test Type, 2022-2031
  • Figure 45: Latin America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2023-2031
  • Figure 46: Latin America Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 47: Latin America Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
  • Figure 48: Latin America Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2031
  • Figure 49: Latin America Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Indication, 2023 and 2031
  • Figure 50: Latin America Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Diagnostic Test Type, 2023 and 2031
  • Figure 51: Latin America Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 52: Latin America Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 53: Latin America Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Diagnostic Test Type, 2022-2031
  • Figure 54: Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2023-2031
  • Figure 55: Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 56: Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
  • Figure 57: Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2031
  • Figure 58: Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Indication, 2023 and 2031
  • Figure 59: Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Diagnostic Test Type, 2023 and 2031
  • Figure 60: Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 61: Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 62: Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Diagnostic Test Type, 2022-2031